Pending Policies - Surgery


Artificial Intervertebral Disc

Number:SUR712.028

Effective Date:11-15-2017

Coverage:

*CAREFULLY CHECK STATE REGULATIONS AND/OR THE MEMBER CONTRACT*

Cervical Artificial Intervertebral Disc

Single Level

Insertion of a single level cervical artificial intervertebral disc, using a disc approved by the U.S. Food and Drug Administration (FDA)*, may be considered medically necessary for patients when ALL of the following criteria are met:

1. The patient is skeletally mature; AND

2. The disc will be used for single-level reconstruction following cervical discectomy within the C3-C7 region; AND

3. The patient has intractable radiculopathy and/or myelopathy due to herniated disc or osteophyte formation; AND

4. The patient has failed at least six weeks of conservative therapy; AND

5. Symptomatic nerve root and/or spinal cord compression are documented by ALL the following:

a) Neck and/or arm pain; and

b) Functional and/or neurological deficit; and

c) Radiographic imaging (e.g., Computed Tomography (CT), Magnetic Resonance Imaging (MRI), x-rays, etc.).

Two Level

Insertion of a cervical artificial intervertebral disc at two contiguous levels, using a disc specifically approved for two contiguous levels by the U.S. Food and Drug Administration (FDA)*, may be considered medically necessary for the treatment of symptomatic degenerative disc disease when ALL of the following criteria are met:

1. The patient is skeletally mature; AND

2. The disc will be used for reconstruction at two contiguous level following cervical discectomy within the C3-C7 region; AND

3. The patient has intractable radiculopathy and/or myelopathy due to herniated disc or osteophyte formation; AND

4. The patient has failed at least six weeks of conservative therapy; AND

5. Symptomatic nerve root and/or spinal cord compression is documented by ALL the following:

a) Neck and/or arm pain; and

b) Functional and/or neurological deficit; and

c) Radiographic imaging (e.g., Computed Tomography (CT), Magnetic Resonance Imaging (MRI), x-rays, etc.).

*NOTE: Please refer to the Regulatory Status section for specific product information.

Artificial intervertebral cervical disc is considered experimental, investigational and/or unproven for all other indications, including but not limited to, more than Two Level use whether done simultaneously or at different times.

Lumbar Artificial Intervertebral Disc

Lumbar artificial intervertebral disc, using a disc that is U.S. Food and Drug Administration (FDA) cleared and used in accordance with the FDA label, may be considered medically necessary for patients who meet ALL of the following criteria:

1) Skeletally mature; AND

2) Degenerative disc disease at only 1 level in the lumbar spine, from L3-S1, confirmed by radiographic studies (CT, MRI, x-rays, etc.); AND

3) Disc will be used for single-level reconstruction following lumbar discectomy within the L3-S1 region; AND

4) Have no more than Grade 1 (0-25%) spondylolisthesis at the involved level; AND

5) Minimum Oswestry Disability Index (ODI) score equal to or greater than 40; AND

6) Radicular back/leg pain that has failed a minimum of 6 months of conservative treatment.

Artificial intervertebral lumbar disc is considered experimental, investigational and/or unproven for all other indications, including but not limited to, multilevel use whether done simultaneously or at different times.

Description:

Cervical Artificial Intervertebral Disc

Several prosthetic devices are currently available for artificial intervertebral disc arthroplasty (AIDA) of the cervical spine. AIDA is proposed as an alternative to anterior cervical discectomy and fusion (ACDF) for patients with symptomatic cervical degenerative disc disease (DDD).

Background

Cervical DDD is a manifestation of spinal spondylosis that causes deterioration of the intervertebral discs of the cervical spine. Symptoms of cervical DDD include arm pain, weakness, and paresthesias associated with cervical radiculopathy. Disc herniation, osteophytes, kyphosis, or instability that compress the spinal cord can result in myelopathy, which is manifested by subtle changes in gait or balance, and in severe cases, leads to weakness in the arms or legs, and numbness of the arms or hands. The prevalence of DDD secondary to cervical spondylosis increases with age. An estimated 60% of individuals older than 40 years have radiographic evidence of cervical DDD. By age 65, 95% of men and 70% of women have at least 1 degenerative change evident at radiographic examination. It is estimated that approximately 5 million adults in the United States are disabled to an extent by spine-related disorders, although only a small fraction of those are clear candidates for spinal surgery. Cervical DDD is initially treated conservatively using noninvasive measures (e.g., rest, heat, ice, analgesics, anti-inflammatory agents, exercise). If symptoms do not improve or resolve in 6 weeks or more, or if they progress, surgical intervention may be indicated. Candidates for surgical intervention have chronic pain or neurologic symptoms secondary to cervical DDD and no contraindications for the procedure.

Anterior cervical discectomy and fusion (ACDF) is currently considered the definitive surgical treatment for symptomatic DDD of the cervical spine. The goals of ACDF are to relieve pressure on the spinal nerves (decompression) and to restore spinal column alignment and stability. Resolution of pain and neurologic symptoms may be expected in 80% to 100% of ACDF patients. ACDF involves an anterolateral surgical approach, decompression of the affected spinal level, discectomy, and emplacement of either autograft or allograft bone in the prepared intervertebral space to stimulate healing and eventual fusion between the vertebral endplates. A metal anterior cervical plate is attached to the adjoining vertebral bodies to stabilize the fusion site, maintain neck lordosis, and reduce the need for prolonged postoperative brace application that is needed following ACDF without an anterior plate. The choice of bone material for interbody fusion in ACDF has important clinical implications. Allograft bone has several drawbacks, including a small (albeit, unproven) risk of infectious disease transmission; possible immunologic reaction to the allograft, and possible limited commercial availability of appropriate graft material. In contrast, the use of autograft bone in ACDF has potentially substantial morbidities at the harvest site, generally the iliac crest. These morbidities include moderate-to-severe, sometimes prolonged pain; deep infection; adjacent nerve and artery damage; and increased risk of stress fracture. Although there may be slight differences between autograft and allograft sources in the postoperative rate of union, clinical studies demonstrate similar rates of postoperative fusion (90%-100%) and satisfactory outcomes for single-level, anterior-plated ACDF, using either bone source. Thus, the choice of graft material involves a trade-off between the risks specific to autograft harvest versus those specific to use of allograft material. Biomechanical modeling studies have suggested that altered adjacent segment kinematics following fusion may lead to adjacent-level DDD; however, the clinical relevance of these changes has not been established.

Artificial intervertebral disc arthroplasty (AIDA) is proposed as an alternative to ACDF for patients with symptomatic cervical DDD. In AIDA, an artificial disc device is secured in the prepared intervertebral space rather than in bone. An anterior plate is not placed to stabilize the adjacent vertebrae, and postsurgical external orthosis is usually not required. It is hypothesized that AIDA will maintain anatomic disc space height, normal segmental lordosis, and physiological motion patterns at the index and adjacent cervical levels. The potential to reduce the risk of adjacent-level DDD above or below a fusion site has been the major rationale driving device development and use. Disc arthroplasty and ACDF for single-level disease have very similar surgical indications, primarily unremitting pain due to radiculopathy or myelopathy, weakness in the extremities, or paresthesia. However, the chief complaint in AIDA candidates should be radicular or myelopathic symptoms in the absence of significant spondylosis. Patients with advanced spondylosis or hard disc herniations have a separate pathologic condition and require a different surgical approach.

Regulatory Status

The Prestige® ST Cervical Disc (Medtronic) received U.S. Food and Drug Administration (FDA) premarket application (PMA) approval as a class III device in 2007. The Prestige ST Cervical Disc is composed of stainless steel and is indicated in skeletally mature patients for reconstruction of the disc from C3-C7 following single-level discectomy. The device is implanted via an open anterior approach. Intractable radiculopathy and/or myelopathy should be present, with at least 1 of the following items producing symptomatic nerve root and/or spinal cord compression as documented by patient history (e.g., pain [neck and/or arm pain], functional deficit, and/or neurologic deficit) and radiographic studies (e.g., magnetic resonance imaging [MRI], computed tomography [CT], x-rays): herniated disc and/or osteophyte formation. The FDA has required the Prestige disc manufacturer to conduct a 7-year postapproval clinical study of the safety and function of the device and a 5-year enhanced surveillance study of the disc to more fully characterize adverse events (AEs) in a broader patient population.

The Prestige® LP artificial cervical disc was approved by the FDA in 2014. The Prestige® LP differs from the original Prestige cervical disc in terms of material and fixation. The LP implant is composed of a proprietary titanium-ceramic composite and has 2 rails that press-fit into holes created during the surgical procedure.

Another disc arthroplasty product, the ProDisc-C® (Synthes Spine) received FDA PMA approval in 2007. As with the Prestige ST Cervical Disc, the FDA approval of ProDisc-C is conditional on 7-year follow-up of the 209 subjects included in the noninferiority trial (discussed in Rationale section), 7-year follow-up on 99 continued access subjects, and a 5-year enhanced surveillance study to more fully characterize AEs when the device is used under general conditions of use. The postapproval study reports are to be delivered to the FDA annually.

The Bryan® Cervical Disc (Medtronic Sofamor Danek) consists of 2 titanium-alloy shells encasing a polyurethane nucleus and has been available outside of the United States since 2002. The Bryan Cervical Disc was approved by the FDA in 2009 for treatment using an anterior approach of single-level cervical DDD defined as any combination of the following: disc herniation with radiculopathy, spondylotic radiculopathy, disc herniation with myelopathy, or spondylotic myelopathy resulting in impaired function and at least 1 clinical neurologic sign associated with the cervical level to be treated, and necessitating surgery as demonstrated using CT, myelography and CT, and/or MRI. Patients receiving the Bryan cervical disc should have failed at least 6 weeks of nonoperative treatment before implantation of the Bryan cervical disc. As a condition for approval of this device, the FDA required the manufacturer to extend its follow-up of enrolled subjects to 10 years after surgery. The study will involve the investigational and control patients from the pivotal investigational device exemption (IDE) study arm, as well as the patients who received the device as part of the continued access study arm. In addition, the manufacturer must perform a 5-year enhanced surveillance study of the BRYAN® Cervical Disc to more fully characterize AEs when the device is used in a broader patient population.

In more recent years, continued FDA approval requires completion of 2 postapproval studies. One study provides extended follow-up of the premarket pivotal cohort out to 7 years. The second study provides 10-year enhanced surveillance of AE data. Continued approval is contingent on submission of annual reports, which include the number of devices sold, heterotopic ossification, device malfunction, device removal, or other serious device-related complications, and analysis of all explanted discs. The following have received FDA approval:

The PCM [porous-coated motion] Cervical Disc® (NuVasive) received FDA approval in 2012 (P100012). The PCM® is a semi-constrained device consisting of 2 metal (cobalt-chromium alloy) endplates and a polyethylene insert that fits between the endplates.

Secure®-C (Globus Medical) was approved in 2012 (P100003). The Secure®-C is a 3 piece semi-constrained device with 2 metal (cobalt chromium molybdenum alloy) endplates and a polyethylene insert.

The Mobi-C® (LDR Spine) received FDA approval in 2013. Mobi-C® is 3-piece semiconstrained device with metal (cobalt-chromium alloy) endplates and a polyethylene insert. The Mobi-C® is approved for 1 (P110002) or 2 level (P110009) disc replacement.

A number of other devices are under study in FDA IDE trials in the United States, including: Kineflex C® Cervical Artificial Disc Implant (Spinal Motion); Discover (DePuy); NeoDisc™ (NuVasive); Freedom® Cervical Disc (AxioMed); and M6-C (Spinal Kinetics).

Updates to the regulatory status of these devices can be viewed online using FDA product code MJO.

Lumbar Artificial Intervertebral Disc

Total disc replacement, using an artificial intervertebral disc designed for the lumbar spine, is proposed as an alternative to fusion in patients with persistent and disabling nonradicular low back pain.

Background

When conservative treatment of degenerative disc disease fails, a common surgical approach is spinal fusion; more than 200,000 spinal fusions are performed each year. However, the outcomes of spinal fusion have been controversial over the years, in part due to the difficulty in determining if a patient's back pain is related to DDD and in part due to the success of the procedure itself. In addition, spinal fusion alters the biomechanics of the back, potentially leading to premature disc degeneration at adjacent levels, a particular concern for younger patients. During the past 30 years, a variety of artificial intervertebral discs have been investigated as an alternative approach to fusion. This approach, also referred to as total disc replacement or spinal arthroplasty, is intended to maintain motion at the operative level once the damaged disc has been removed and to maintain the normal biomechanics of the adjacent vertebrae.

Potential candidates for artificial disc replacement have chronic low back pain attributed to DDD, lack of improvement with non-operative treatment, and none of the contraindications for the procedure, which include multilevel disease, spinal stenosis, or spondylolisthesis, scoliosis, previous major spine surgery, neurologic symptoms, and other minor contraindications. These contraindications make artificial disc replacement suitable for a subset of patients in whom fusion is indicated. Patients who require procedures in addition to fusion, such as laminectomy and/or decompression, are not candidates for the artificial disc.

Use of a motion-preserving artificial disc increases the potential for a variety of types of implant failure. These include device failure (device fracture, dislocation, or wear), bone-implant interface failure (subsidence, dislocation-migration, vertebral body fracture), and host response to the implant (osteolysis, heterotopic ossification, and pseudotumor formation).

Regulatory Status

While a number of artificial intervertebral discs in the lumbar spine have been used internationally, only 3 devices (activL®, Charité®, ProDisc®-L) have been approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. Because the long-term safety and effectiveness of these devices were not known, approval was contingent on completion of postmarketing studies. The activL® (Aesculap Implant Systems), Charité® (DePuy), and ProDisc®-L (Synthes Spine) devices are indicated for spinal arthroplasty in skeletally mature patients with degenerative disc disease (DDD) at 1 level; activL® and Charité® are approved for use in levels L4-S1; and ProDisc®-L is approved for use in levels L3-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographs. The INMOTION® lumbar artificial disc (DePuy Spine) is a modification of the Charité® device with a change in name under the same premarket approval. Production under the name Charité® was stopped in 2010. The INMOTION® is not currently marketed in the United States. The Maverick™ artificial disc (Medtronic) is not marketed in the United States due to patent infringement litigation. The metal-on-metal FlexiCore® artificial disc (Stryker Spine) has completed the investigational device exemption trial as part of the FDA approval process and is currently being used under continued access. Kineflex-L™ (Spinal Motion) is a 3-piece, modular, metal-on-metal implant. An FDA advisory committee meeting on the Kineflex-L was scheduled for July 2013, but was cancelled without explanation. FDA product code: MJO.

This may not be an “all inclusive” list of artificial disc devices and is subject to change. Refer to the FDA web site at <www.fda.gov> for additional information on devices.

Rationale:

Cervical Artificial Intervertebral Disc

Prestige Cervical Disc

The Prestige disc received U. S. Food and Drug Administration (FDA) marketing approval in 2007. Information on the Prestige cervical disc is available from a published report of the pivotal trial and from Medtronic’s premarket approval (PMA) application to FDA. (5,8) These documents report results from a randomized study of anterior cervical fusion (with allograft bone and plate stabilization) versus the artificial cervical disc for patients with nonaxial pain and other symptoms secondary to radiculopathy or myelopathy that did not improve with a minimum 6 weeks of conservative therapy. The study was designed as a randomized, nonblinded noninferiority trial with a 10% margin. Results for 137 investigational and 148 control patients who were evaluated at 2 years postsurgery were presented to the FDA in the PMA application. These patients represented about half of the total population (276 and 265, respectively), while the peer-reviewed article reported on about 75% of cases.

Three primary outcome variables were used in the Prestige trial: the Neck Disability Index (NDI), neurologic status, and functional spinal unit (FSU) height. The NDI is a validated multidimensional instrument that measures the effects of pain and disability on a patient’s ability to manage everyday life. (9) It is a modification of the Oswestry Disability Index (ODI), based on the response to 10 questions that focus on neck pain intensity, personal care, lifting, reading, headaches, concentration, work, driving, sleeping, and recreation. The response to each question ranges from 1 to 5, with a lower numeric score representing a better pain and disability status for that variable. A total NDI score is obtained by adding individual question scores and dividing by the maximum total of 50, if all questions are answered. Therefore, NDI scores range from 0% to 100%, with a lower percentage indicating less pain and disability. The neurologic status is a composite measure of motor function, sensory function, and deep tendon reflexes. It is used to judge if patients are within normal parameters for those categories based on physiologic measurement. Neurologic success in the Prestige trial was based on postoperative maintenance or improvement of condition compared with preoperative status for each component. The anterior FSU height is a radiographic measure of interdiscal space. Comparison of the immediate postoperative FSU height with the 6-week postoperative value shows whether the disc space has decreased, which indicates that graft or device subsidence has occurred. Secondary outcome measures include the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Mental and Physical Component Summary scores, neck and arm pain status, patient satisfaction, patient global perceived effect, gait assessment, foraminal compression test, adjacent level stability and measurements, return to work, and physician’s perception.

Both data sources for the Prestige disc trial showed equivalent results. Thus, 81% of both groups showed at least a 15-point improvement for the NDI, demonstrating noninferiority to fusion but not superiority. Similarly, the FSU height measure also demonstrated evidence of noninferiority but not superiority. Neurologic status showed noninferiority and statistical superiority for the disc compared with fusion. This contributed to the overall success composite end point demonstrating superiority for the disc compared with fusion. While maintained or improved neurologic status was more frequent following AIDA, it was unclear whether examiners were blinded. Most secondary outcome measures for the disc were deemed noninferior to ACDF, but none was statistically superior. Perioperative results and adverse events (AEs) were similar in both groups, with very few serious complications.

Five-year and 7-year follow-up of participants in this clinical trial were reported by Burkus et al. in 2010 and 2014, respectively. (10, 11) All participants were followed up in this FDA-regulated postapproval study. Outcomes at 60 months were reported on approximately half of the original randomized controlled trial (RCT) participants. Patients who had not yet reached that point in their follow-up for the 2010 publication were included in the 2014 report. Follow-up at 84 months was obtained in 73% of study participants (212 AIDA, 183 ACDF). Overall success rates at 78 months were 72.6% for the Prestige disc and 60.0% for ACDF (p=0.008), the NDI improved by 37.5 for the Prestige disc compared with 31.9 for ACDF (p=0.002), and neurologic success was greater in the Prestige disc group (88.2% vs 79.7%, p=0.011). There was no significant difference between the two groups in NDI success rates at 84 months (p=0.109) or in work status. The rate of secondary surgeries at the initial treatment level was lower for Prestige compared with ACDF (4.8% vs 13.7%. p<0.001), but there was no significant difference in the rate of adjacent level surgeries (3.9% vs 5.4%).

ProDisc-C

Murrey et al. reported 2-year results from the pivotal FDA randomized noninferiority trial to determine the safety and efficacy of ProDisc-C in comparison with ACDF. (12) In this trial, 103 patients received the ProDisc-C implant and 106 were treated with fusion; participants were blinded to intervention until following surgery. Follow-up between 6 weeks and 2 years was reported to be 85% in the summary of safety and effectiveness data presented to the FDA. (13) Reasons for the loss to follow-up were not described but appear to have included 2 patients in the ProDisc-C group who had the implant removed and 5 patients in the fusion group who had undergone additional surgical procedures to modify the original implant. Non-inferiority was achieved for the FDA-defined combined end point of neurologic examination, NDI, AEs, and device success, with 72% of ProDisc-C and 68% of fusion patients achieving success in all 4 component end points. Clinical outcomes at 24 months of follow-up were reported to be similar in the ProDisc-C and fusion groups for the following components: neurologic success (91% vs 88%), NDI (21.4 vs 20.5 points), reduction in pain scores (e.g., 46-mm vs 43-mm reduction in neck pain on a visual analog scale [VAS]), and patient satisfaction (83 mm vs 80 mm, respectively).

Four-year interim follow-up of participants in this clinical trial were reported by Delamarter et al. 2010. (14) All participants in the clinical trial were followed up in this FDA-regulated postapproval study. At 48 months, follow-up rates for ProDisc-C and ACDF were 63% and 46.2% respectively. It was not reported what proportion of these patients had not yet reached 48 months postsurgery or were truly lost to follow-up at that time point. Also included in this report was 24-month follow-up on 77% of 136 continued access patients who received the ProDisc-C after the clinical trial. Clinical outcomes were similar between the 3 groups, with point estimates in favor of ProDisc-C. The NDI at 48 months was 20.3 for ProDisc-C versus 21.2 for ACDF. Neurologic success was achieved in 88.9% of ProDisc-C patients in comparison with 74.4% of ACDF patients (p=0.067). There was a cumulative incidence of additional surgeries of 2.9% (3 patients) in the ProDisc-C group and 11.3% (12 patients) in the ACDF group. Two patients were converted to fusion with removal of the device; 1 patient had decompression with supplemental fixation without removal of the device. At 48 months, 5 ProDisc-C patients (7.7%) were found to have bridging bone.

Five-year results of this trial were published in 2013 with follow-up rates of 72.7% for ProDisc-C and 63.5% for ACDF. (15, 16) Outcomes on the NDI were found to be similar (50-60% improved), along with VAS for arm pain (18 for both groups) and scores on the SF-36. VAS for neck pain was modestly improved with ProDisc-C compared with ACDF (21 vs 30), although the proportion of patients who achieved a clinically significant improvement in neck pain was not reported. There was a lower percentage of patients with ProDisc-C who had secondary surgery at either the index or adjacent level (2.9% vs 14.5%).

Nabhan et al. reported 1-year clinical and radiologic results of 49 patients randomized to receive a ProDisc-C artificial disc or fusion. (17) Measurements taken at 3, 6, 12, 24, and 52 weeks showed a decrease in segmental motion at the index level in both groups over the first 12 weeks after surgery; at 52 weeks, segmental translation (xyz axis) was about 1 mm greater in the ProDisc-C group. Clinical results were similar in the 2 groups, with a 70% reduction in neck pain and 86% reduction in arm pain in the ProDisc-C group and a 68% reduction in neck pain and 83% reduction in arm pain in the ACDF group. As noted by the authors, longer follow-up is needed to determine the effect of this implant on cervical motion and stress at adjacent levels.

Bryan Cervical Disc

Two- and 4-year results have been published from the IDE trial for the Bryan disc. (18, 19) The trial employed inclusion/exclusion criteria and a composite outcome identical to the ProDisc-C trial. A total of 582 patients were randomized to the Bryan disc (n=290) or ACDF (n=292). Thirty-seven patients declined surgery in the AIDA group; 80 patients declined surgery in the ACDF group. Twelve patients crossed over from AIDA to ACDF, 1 crossed over from ACDF to AIDA, and 2 patients were excluded from ACDF due to protocol violations, leaving 242 patients who underwent AIDA and 223 who underwent ACDF. In the AIDA and ACDF arms, mean age (44.4 and 44.7 years), sex (45.5% and 51.1% men) and NDI scores (51.4 and 50.2, all respectively) were similar. All but 1 patient who underwent AIDA and 3 patients in the ACDF arm had documented neurologic abnormalities. After 2 years’ follow-up, data were available for 230 (95%) patients from the AIDA group and 194 (87%) who underwent ACDF. The overall success outcome was achieved more often after AIDA (82.6% vs 72.7%), with a mean 4.1-point greater improvement in the NDI scores. As measured by the composite end point, AIDA was superior to ACDF. At 24 months, neck pain scores were lower following AIDA, while other secondary outcomes were similar. AE rates were similar in the 2 arms—1.7% in AIDA and 3.2% in ACDF arms, requiring revision.

In 2011, 4-year follow-up from the IDE trial was reported for 181 patients (75% of 242) who received the Bryan disc and 138 patients (62% of 223) who underwent ACDF. (19) It was reported that 25% of AIDA and 38% of the ACDF patients failed to return for follow-up at 48 months, due in part to FDA and institutional review board approvals and the need for additional patient consent for the continuation study. Overall success was defined as an improvement of 15 or more points in the NDI, neurologic improvement, no serious AEs related to the implant or surgical implantation procedure, and no subsequent surgery or intervention that would be classified as a treatment failure. The 4-year overall success rates were significantly greater in the Bryan (85.1%) than the ACDF (72.5%) group. This finding was driven largely by differences in the NDI success (90.6% of arthroplasty, 79.0% of ACDF). Neurologic success rates were not different between the groups. Arm pain improved from a baseline of 71.2 in both groups to 16.6 for the Bryan disc and 22.4 for ACDF, the difference between groups was statistically significant. The improvement in neck pain scores was also significantly better in the Bryan disc group (from 75.4 to 20.7) compared with patients with fusion (from 74.8 to 30.6). Improvement in the SF-36 Physical Component Summary score was also significantly greater in the arthroplasty group (15.8 vs 13.1). There was no significant difference in additional surgical procedures at either the index (3.7% Bryan, 4.5% ACDF) or adjacent (4.1% Bryan, 4.1% ACDF) levels. FDA-required follow-up will continue for 10 years after the index surgery.

In the discussion of this article, the authors comment that failure of other joint arthroplasty prostheses does not typically occur until at least 5 to 10 years postoperatively and that spinal arthroplasties also need to have serial assessments to determine whether complications such as wear-related failures, device fatigue, or spinal instability have developed. They conclude that as with any motion-sparing device, “longer-term follow-up is necessary for assessment of potential problems related to bearing surface wear.”

A post hoc subgroup analysis of 199 participants with myelopathy from the Prestige ST (n=111) and Bryan (n=88) trials found similar improvement in postoperative neurologic status and gait at 24 months (Prestige ST: AIDA 90% [95% confidence interval (CI), 79% to 97%] and ACDF 81% [95% CI, 65% to 92%]; Bryan: AIDA 90% [95% CI, 76% to 97%] and ACDF 77% [95% CI, 76% to 97%]). (20) The authors noted that "although short-term results of cervical disc arthroplasty appear encouraging, studies with at least five to ten years of follow-up are required before cervical disc replacement can be viewed as a standard treatment for disc-based cervical myelopathy."

In 2010, Goffin et al. reported 4- and 6-year follow-up from phase 1 and phase 2 trials of the Bryan disc. (21) The total potential patient population for long-term follow-up was 98 patients (89 with 1-level and 9 with 2- level); 59 of the patients were at least 6 years postoperative. Although 4 patients from the phase 1 study declined to participate in the extended follow-up study, their results were included in the safety data. Mean neck pain at 4 and 6 years postoperatively was 2.2 and 2.0, respectively. Mean arm pain at 4 and 6 years was 2.4 and 2.3, respectively. Six patients experienced events that were believed to be related to the device, including minor device migration, device removal, hoarseness, and vocal cord paralysis, while 3 of the 6 cases involved pain or neurologic symptoms. The prosthesis was removed from 1 patient at 6 years after the index surgery because of progressive spinal cord compression due to recurrent posterior osteophyte formation. About 90% of patients were classified as having excellent or good outcomes at 4 and 6 years. The success rate estimated by Kaplan-Meier analysis was 94% at 7 years following surgery.

Two-Level Bryan Cervical Disc

In 2009, Cheng et al. reported 2-year follow-up from an RCT of the Bryan disc versus ACDF with autograft in 65 patients with 2-level disc disease. (22) One patient from the arthroplasty group and 2 patients from the ACDF group were lost to follow-up. Neck pain and arm pain measured by VAS tended to be better in the Bryan group (1.8 and 1.9, respectively) than the ACDF group at 12-month follow-up (2.5 and 2.4, respectively) and continued to improve at 2-year follow-up (Bryan, 1.5 and 1.4; ACDF, 2.6 and 2.7, respectively). NDI and SF-36 Physical Component Summary scores were also significantly better in the Bryan group at both 12- and 24-month follow-up. These results support the short-term safety of the Bryan disc in 2-level disc disease; longer-term results are needed to evaluate the safety and efficacy of this device in comparison with ACDF for 2-level disc disease.

Kineflex-C

In 2011, Coric et al. reported the 24-month pivotal multicenter randomized IDE trial of the MoM Kineflex-C artificial disc (n=136), compared with ACDF performed with allograft and anterior plate (n=133). (23) There were no significant differences between the Kineflex-C and ACDF groups for operative time, blood loss, length of hospital stay, or reoperation rate at the index level. The overall success rate was significantly greater in the Kineflex-C group (85%) compared with the ACDF group (71%). (Overall success was defined as a composite measure of neurologic evaluation, greater than 20% improvement in NDI, no device failure, no reoperation at the index level, and no major device-related AE.) There were 6 index- level reoperations (5%) in the Kineflex-C group, including 1 case of metal sensitivity and 2 for device migration. There were 7 index-level surgeries (7.6%) in the ACDF group, including 3 for pseudarthrosis and 4 for instrumentation failure (removal or revision of the original anterior plate and screw construct). There was no significant difference between groups in VAS pain scores or NDI. Although fewer Kineflex- C patients showed severe adjacent-level radiographic changes (9% vs 24.8%), there was no significant difference between the groups in the adjacent-level reoperation rate (7.6% for the Kineflex-C group and 6.1% for the ACDF group) at short-term follow-up.

The need for longer-term studies remains to assess device failure and other long-term complications. An accompanying editorial notes that while the 24-month IDE trials of artificial discs have been well done, and these new motion-saving mechanical devices may potentially be better than ACDF, a number of complications can occur with arthroplasty that include dislodgement, vertical vertebral body fracture, device failure, and heterotopic ossification. (24) Given that no mechanical device has an infinite lifespan, and we do not know the failure rate, timeframe, or consequences of failure of cervical arthroplasty devices, a longer period of scientific scrutiny was advised to determine the real efficacy of artificial cervical discs.

Mobi-C

Mobi-C is the only artificial disc that is approved for 1- or 2-level cervical disc disease. The 1-level Mobi-C trial randomized 169 patients to receive AIDA and 87 to ACDF. (25) Patient characteristics were generally similar to the other trials. Patient with multilevel disease or previously treated cervical disease were excluded from the trial. At 24 months, the follow-up rate was 93%. Designed as a noninferiority trial, noninferiority criteria were met for NDI mean improvement, percent NDI success (≥15-point improvement), and overall success. The overall protocol-specified success rate was higher in the Mobi-C group than the ACDF group (73.7% vs 65.3%), which met noninferiority criteria but did not meet superiority criteria. Cumulative subsequent surgical interventions at the index level were numerically lower in the AIDA group than the ACDF group (1.2% vs 6.2%).

Two- and 4-year results from the 2-level Mobi-C IDE trial were reported by Davis et al. in 2013 and 2014, respectively. (26, 27) In this noninferiority trial, 225 patients received the Mobi-C device at 2 contiguous levels and 105 patients received 2-level ACDF. At 24 months, the follow-up rate was 98.2% for the AIDA group and 94.3% for the ACDF group. At 48 months, the follow-up rate was 89.0% for AIDA and 81.2% for the ACDF group. Both groups showed significant improvement in NDI score, VAS neck pain, and VAS arm pain from baseline to each follow-up point, with Mobi-C meeting the noninferiority margin. Subsequent testing for superiority showed that AIDA patients had significantly greater improvement than ACDF patients in NDI and had higher NDI success rates (79.3% vs 53.4% at 48 months, p<0.000) and overall success rates (66.0% vs 36.0% at 48 months) at all time points. AIDA resulted in significantly greater improvement in VAS neck pain at 3 and 6 months postoperatively but not at 12, 24, 36, or 48 months. Arm pain scores did not differ between the groups. The Mobi-C group had a lower reoperation rate (4.0% vs 15.2% p<0.000). At 48 months, adjacent-level degeneration was observed in 41.5% of AIDA patients and 85.9% of ACDF patients with available radiographs, while 25.6% of AIDA patients showed clinically relevant heterotopic ossification.

Post hoc analysis of data from the pivotal 1- and 2-level Mobi-C trials was reported by Bae et al. in 2015. (28) Comparison showed no significant difference between 1- and 2-level AIDA on clinical outcomes (NDI, VAS, SF-12), major complication rates (4.3% for 1-level AIDA, 4.0% for 2-level AIDA), or subsequent surgery rates (3.0% of 1-level, 4.0% of 2-level). Clinically relevant heterotopic ossification was observed in 23.8% of 1-level patients and 25.7% of 2-level patients. Huppert et al. compared outcomes between single- (n=175) and multilevel (2-4 levels, n=56) AIDA with the Mobi-C device in a prospective multicenter study from Europe. (29) The age of the patients was significantly higher, and the time since symptom onset was significantly longer in the multilevel group. At 2 years, there was no significant difference between groups for the radicular VAS, cervical VAS, or NDI. Range of motion was similar in the 2 groups. The overall success rate was 69% for the single-level group and 69% for the multilevel groups. There was a trend for more patients in the single-level group to return to work (70% vs 46%), and for the return to work to occur sooner (4.8 months vs 7.5 months). A similar percentage of patients underwent adjacent-level surgery (2.3% for single-level and 3.6% for multilevel).

Porous Coated Motion Cervical Disc

Results of the 2-year FDA-regulated multicenter randomized noninferiority trial of the porous coated motion (PCM) Cervical Disc were reported by Phillips et al. in 2013. (30) The investigator and surgical staff were not blinded to treatment assignment, and patients were informed of the treatment assignment after surgery. Of the 416 patients who were randomized (224 PCM, 192 ACDF), 340 (82% [189 PCM, 151 ACDF]) were per protocol for the 24-month primary end point of overall success. Overall success was defined as at least 20% improvement in NDI; absence of reoperation, revision, or removal; maintenance or improvement in neurologic status; and absence of radiographic or major complications during the 24- month follow-up period. At 24 months, overall success was 75.1% in the PCM group and 64.9% in the ACDF group, which met both the noninferiority and superiority criteria. There was a trend toward a greater neurologic success rate in the PCM group (94.7%) compared with ACDF (89.5%, p=0.10). There was no significant difference between the groups for VAS pain scores, SF-36 component scores, or implant- or surgery-related AEs (5.2% PCM vs 5.4% ACDF). Patients with prior fusion were included in this study. Overall success for the two subgroups in this analysis was similar (65.4% PCM and 64.3% ACDF).

SECURE-C

The FDA-regulated SECURE-C trial was a multicenter nonblinded noninferiority trial with151 patients randomized to receive AIDA and 140 patients randomized to ACDF. (31 32) An additional 89 nonrandomized patients were included in the published data. (32) Patients with multilevel disease or previously treated cervical disease were excluded from the trial. Overall success was defined by the FDA as a 15-point or more improvement in NDI; absence of reoperation, revision, or removal; stable or improved neurologic status, and absence of radiographic or major complications during the 24-month follow-up period. At 24 months, the follow up rate was 87%. Noninferiority criteria were met for NDI mean improvement, rate of NDI success (89.2% vs 84.5%), neurologic success (96.0% vs 94.9%), and overall success (83.8% vs 73.2%, AIDA vs ACDF, all respectively, posterior probability of 98.1% by Bayesian analysis) using FDA-defined criteria. The overall success rate, as specified in the protocol at 24 months (>25% improvement in NDI, no removals and no complications) was also higher in the SECURE-C group than the ACDF group (90.1% vs 71.1%), which met both noninferiority criteria, as well as superiority criteria (posterior probability of 100% by Bayesian analysis). Cumulative secondary surgical interventions at the treated level were lower in the AIDA group than the ACDF group (2.5% vs 9.7%).

Adverse Events

Adjacent Segment Degeneration

A key question is whether cervical disc arthroplasty reduces adjacent segment degeneration, which is the hypothetical advantage of motion-preserving artificial discs. In a 2010 report, Jawahar et al. evaluated the incidence of adjacent segment degeneration in 93 patients with 1- or 2-level cervical DDD who had participated in 1 of 3 FDA-regulated RCTs (Kineflex-C, Mobi-C, or Advent Cervical Disc). (33) ACDF was performed using the modified Smith Robinson technique using cortical bone allograft. VAS pain scores, NDI, and cervical spine radiographs were collected at 6 weeks and at 3, 6, 12, 24, 36, and 48 months after surgery. Success was defined as a composite of reduction by more than 30 points in both VAS (100- point scale) and NDI, absence of neurologic deficits, and no further intervention at the index level.

Patients developing new complaints pertaining to cervical spine were worked up for possible adjacent segment disease with repeat magnetic resonance imaging of the cervical spine and electrophysiologic studies. Only those patients who demonstrated clinical and radiologic stigmata of adjacent segment disease, and received active intervention for its management, were included in the statistical analysis.

At a median follow-up of 37 (range, 24-49) months, 73.5% of ACDF and 71% of arthroplasty patients satisfied the criteria for clinical success. The median symptom-free survival period was 39.8 months for ACDF and 38.1 months for arthroplasty patients. There was no statistical difference between the groups for VAS or NDI at the final follow-up. The mean improvement in NDI was 43 points for ACDF and 45 points for arthroplasty; the mean improvement in VAS was 62 points for ACDF and 62 for arthroplasty. At final follow-up, 16% of arthroplasty patients and 18% of ACDF patients were treated for adjacent segment degeneration; these rates were not significantly different. The mean period of freedom from adjacent-level disease was 38 months for both groups.

In 2012, the same group of investigators published a report that included 170 patients (57 ACDF and 113 arthroplasty, with likely overlap in patients from the previous study) with a median follow-up of 42 months (range, 28-54). (34) As in the earlier report, there was no significant difference in adjacent-level disease between ACDF and arthroplasty patients (14% vs 17%, respectively). The mean period of freedom from adjacent-level disease was 46 months after ACDF and 49 months after total disc arthroplasty. Osteopenia and lumbar DDD were found to significantly increase the risk of adjacent level disease.

In 2010, Coric et al. reported outcomes from 98 patients with 1- or 2-level cervical disc disease who had participated in 1 of 3 IDE studies (Bryan, Kineflex/C and Discover cervical disc). (35) Patients were evaluated with neurologic examinations, radiographs, and clinical outcome indices at 1, 3, 6, 12, 24, 36, 48, and 60 months. A minimum follow-up of 24 (range, 24-67) months was available for 90 patients (53 arthroplasty, 41 ACDF). Clinical success, defined as a composite measure consisting of 5 separate components (neurologic, 20% improvement in NDI, no AEs, no reoperation at the index or adjacent level, no narcotic usage at 24-month follow-up) was achieved in 85% of arthroplasty and 70% of ACDF patients (p=0.035). Overall, angular motion was improved by 0.91° in the arthroplasty group and reduced by 7.8° in the ACDF group. In the arthroplasty group, there was a 5.6% incidence of bridging heterotopic ossification (3 cases). There were a similar number of reoperations, with 4 (7.5%) in the combined arthroplasty group (1 at the adjacent level) and 3 (8.1%) in the ACDF group (all at the adjacent level). A 2013 report from this group reported minimum 48-month follow-up (range, 48-108) of 74 patients who had received a Bryan or Kineflex cervical disc. (36) There were no significant differences between the groups in the mean NDI or median VAS scores. There were 3 reoperations (7.3%) at the index (n=1) or adjacent levels (n=2) in the AIDA group and 1 (3%) adjacent level reoperation in the ACDF group.

Results on adjacent level degeneration from the 2-level Mobi-C IDE trial were reported from 225 patients who received the Mobi-C device at 2 contiguous levels and 105 patients who received 2-level ACDF. (26, 27) At 24 months, adjacent-level degeneration was observed in the superior and inferior segments in 13.1% and 2.9% of AIDA patients, respectively. Adjacent-level degeneration was observed in the superior and inferior segments in 33.3% and 18.1% of ACDF patients, respectively. At 48 months, adjacent-level degeneration was observed in 41.5% of AIDA patients and 85.9% of ACDF patients with available radiographs, while 25.6% of AIDA patients showed clinically relevant heterotopic ossification.

Maldonado et al. evaluated adjacent-level degeneration in a prospective cohort study of 85 patients treated with AIDA and 105 treated with ACDF for single-level DDD. (37) The rationale for treatment allocation was not described. At 3 years after surgery, radiographic evidence of adjacent-segment disease was found in 10.5% of patients in the ACDF group and in 8.8% of subjects in the AIDA group (not significantly different). There was no significant difference between groups in VAS arm pain or NDI.

Device Failure

Reports of device failure may emerge with increased use of artificial discs and longer follow-up. One case report describes failure of a Bryan cervical disc due to a fatigue fracture of the flexible polyether urethane sheath at 8 years after implantation. (38) Degradation of the sheath, including surface fissures and full- thickness cracks, has been observed in 27% of retrieved Bryan discs. (39) One case of anterior migration of the Mobi-C disc was reported. (40) Another case was reported of fragmented fracture of the ceramic-on-ceramic Discocerv® (Cervidisc Evolution) at 1 month after implantation. (41) This artificial disc is not available in the United States.

Dysphagia

A lower incidence of dysphagia has been reported with cervical arthroplasty in comparison with ACDF. (42) As part of the IDE trial for the PCM device, patients who underwent arthroplasty (n=151) or ACDF (n=100) self-reported dysphagia severity using the validated Bazaz Dysphagia Score. The arthroplasty group showed a significantly lower incidence of dysphagia at all time points (6 weeks and 3, 6, 12, and 24 months after surgery). For example, at the 6-week follow-up, moderate-to-severe dysphagia was reported in 18.7% of arthroplasty patients compared with 37.3% of ACDF patients, while at 12-month follow-up, moderate-to-severe dysphagia was reported in 4.3% of arthroplasty patients compared with 13.1% of ACDF patients.

Heterotopic Ossification

A meta-analysis of heterotopic ossification (McAfee grade 3-4) after AIDA was published by Chen et al. in 2012. (43) Included in the meta-analysis were 8 studies (617 patients). The pooled prevalence of any heterotopic ossification was 44.6% at 12 months after AIDA and 58.2% at 24 months after AIDA. The pooled prevalence of advanced heterotopic ossification was 11.1% after 12 months and 16.7% after 24 months. Although no publication bias was identified, there was significant heterogeneity in study results.

The largest study included in the meta-analysis evaluated rates of heterotopic ossification in 170 patients who had undergone cervical arthroplasty with 1 of 3 cervical discs (81 Bryan, 61 Mobi-C, 28 ProDisc-C) and had at least 12 months of follow-up. (44) Heterotopic ossification was found in a total of 40.6% of patients; the median time without heterotopic ossification was 27.1 months. Heterotopic ossification occurred in 21% of Bryan patients, 52.5% of Mobi-C, and 71.4% of ProDisc-C patients. This study had several limitations. First, the investigators could not completely discriminate whether the newly developed bone was true heterotopic ossification or a bone mass from normal fusion of the prosthesis to bone. There was also a possibility of underestimating posterior or lateral heterotopic ossification due to limited sensitivity of plain radiographs. In addition, clinical outcomes were not assessed.

Tu et al. assessed heterotopic ossification in a series of 36 patients (52 levels) who had received total disc replacement with the Bryan cervical disc and had completed clinical and radiologic evaluations. (45) Heterotopic ossification was observed in computed tomography images in 50% of the patients at a mean of 19 months of follow-up. However, only 2 treated levels (3.8%) showed a loss of segmental motion (<2°) by dynamic radiography. At a mean of 27 months of follow-up, clinical evaluation indicated a similar clinical success rate in patients who had heterotopic ossification compared with those who did not (94.4% in both groups).

Progressive spinal cord compression due to osteophyte formation has been observed with cervical disc arthroplasty. (21)

The evidence on AEs of cervical AIDA raises questions on the overall risk/benefit ratio for these devices. The potential to reduce adjacent level DDD has been the major rationale driving device development and use of AIDA. Evidence to date has not demonstrated a reduction in adjacent level disease with use of artificial cervical discs.

The rates of device failure and the need for reoperations due to device failure or malfunction are not well defined. Reports of device failure that occur at time periods longer than the average follow-up in the clinical trials highlights the need for longer term studies to further define these AEs.

Heterotopic ossification could potentially have a negative impact on the goal of mobility with AIDA. Studies to date indicate a high rate of heterotopic ossification at short-term follow-up. Longer follow-up with clinical outcome measures is needed to evaluate the clinical significance of heterotopic ossification following AIDA.

Hypersensitivity Reaction

The first reported case of a delayed hypersensitivity reaction to metal ions after disc arthroplasty was in 2009. (46) Although no intracellular or extracellular metal alloy particles were detected in the tissue, the lymphocyte-dominated response was thought to be similar to reactions reported in patients with MoM hip prostheses. The patient had complete resolution of symptoms following implant removal and fusion. In 2011, Guyer et al. reported 4 cases of a lymphocytic reaction to a MoM artificial disc (1 Kineflex-C cervical disc and 3 lumbar) that required revision. (47) The mode of failure was determined to be compression of neural tissue or other adjacent structures by a soft tissue mass. Three patients had a good outcome after the explantation and revision surgery; 1 patient continued to have residual symptoms related to the neural compression caused by the mass. No hypersensitivity reactions have been reported from devices with a polyethene/polyurethane insert or from Prestige stainless steel implants, however, periprosthetic tissue explanted after 1 to 7 years commonly showed focal metallosis.(39)

Subsidence

Extensive bone loss in the vertebral body and device subsidence has been reported as a complication in some patients between 4 and 6 years after cervical arthroplasty. (48)

Summary: Cervical Artificial Intervertebral Disc

After 2 years of follow-up, randomized trials of all the artificial cervical discs met noninferiority criteria as measured by the Neck Disability Index and overall success composite outcome. Mid-term outcomes have been reported on 4 of the devices (Prestige ST, ProDisc-C, Mobi-C, Bryan discs). The trial results are consistent with continued noninferiority of artificial intervertebral disc arthroplasty for all devices and lower cumulative reoperation rates at 4 to 5 years. Longer term results are expected, given the U.S. Food and Drug Administration requirement for 7- to 10-year postapproval studies of the safety and function of the devices, and 5- to 10-year enhanced surveillance study of these discs to more fully characterize adverse events in a broader patient population.

Lumbar Artificial Intervertebral Disc

Guyer et al. (50) conducted a prospective, randomized, multicenter FDA investigational device exemption study of lumbar total disc replacement with the Charité artificial disc versus lumbar fusion, to compare the safety and effectiveness of the artificial disc versus fusion. In 2009 they reported their five-year follow-up data from the original cohort of 375 patients who were randomized to receive treatment for DDD with either a Charité artificial disc or an anterior lumbar interbody fusion (ALIF) with a BAK cage and iliac crest autograft. No statistical differences were found in clinical outcomes between groups. In addition, Charité patients reached a statistically greater rate of part- and full-time employment and a statistically lower rate of long-term disability, compared with BAK patients. Radiographically, the range of motion (ROM) at index- and adjacent levels were not statistically different from those observed at two years postsurgery. The authors concluded that treatment with the artificial disc was not inferior to discectomy and fusion of a single lumber segment using a BAK cage.

David (51) reported a retrospective review to determine the long-term clinical results, radiographic results, and incidence of complications in 106 patient, with a mean age of 36.4 years, who received one-level lumbar total disc replacement (TDR) using a Charité. Mean follow-up time was 13.2 years (range, 10-16.8 years). Of the 106 patients, 87 (82.1%) had either an excellent or good clinical outcome. Of the 96 patients working before surgery, 86 returned to work (89.6%), including 77.8% of patients with hard labor level employment (28 of 36) returning to the same level of work. The mean ROM in flexion-extension was 10.1 degrees, in lateral bending it was 4.4 degrees, and 90.6% of implanted prostheses were still mobile. Eight patients (7.5%) required posterior instrumented fusion. There were 5 cases (4.6%) of postoperative facet arthrosis, 3 cases (2.8%) of subsidence, 3 cases (2.8%) of adjacent-level disease, and 2 cases (1.9%) of core subluxation. The author concluded that this study demonstrated the long-term safety and efficacy of the artificial disc at one level, either L4-L5 or L5-S1. Clinical outcomes and the rate of return to work were excellent overall. The rate of adjacent-level disease requiring surgical intervention was considerably lower (2.8%) compared with reports in the literature for lumbar fusion. As with any surgical procedure, proper indications play a pivotal role in clinical success.

Overall, late complications have been reported for the artificial disc (51/52); however, these complications appear to be infrequent in the 5-10 year postoperative period, and the percentage of patients reporting good to excellent outcomes from artificial disc appears to be in the known range of success for single-level fusion. Resnick and Watters (53) report however, that artificial disc has not resulted in better outcomes than fusion. David (51) reported that long-term data indicate that, while patients may experience adjacent-level degeneration (ALD) with artificial disc, the rate is generally less than that seen with fusion. In addition, reoperation rates following Charité placement have compared to reoperation rates following fusion. David (51) reported reoperation rate of 10.3%. The US Charité IDE study (55) reported reoperation rate of 8.8% over 2 years or more of follow-up; Martin et al (56) reported 19%; Malter et al. (57) reported 15%.

In 2012, Zigler et al. (58) reported the 5-year results of a prospective multicenter study in which patients were randomized to either total disc replacement (TDR) or circumferential fusion for single-level lumbar DDD, as part of an FDA-mandated postmarket approval study to evaluate long-term safety and effectiveness. Two hundred thirty-six patients were treated and followed up for 5 years; 161 TDRs and 75 fusions had been performed in these patients. The primary outcome was a 10-component success end point. Secondary outcome measures included neurological status, secondary surgery, Oswestry Disability Index (ODI), 36-Item Short Form Health Survey (SF-36), visual analog scale (VAS) assessing pain and satisfaction, radiographic data, narcotic use, activity, and recreation status. The overall follow-up rate at 5 years was 81.8%. Study success demonstrated that TDR was noninferior to fusion with a 12.5% margin (p = 0.0099). Both TDR and fusion treatment groups maintained significant improvement on the ODI at 5 years compared with baseline (p < 0.0001). Secondary surgeries at the index level were performed in 12% of fusion patients and 8% of TDR patients. Radiographically, none of the TDRs developed spontaneous fusion. The segmental range of motion following TDR remained within normal range, although it decreased by approximately 0.5° in years 3 to 5. The VAS pain scores decreased from preoperative values by 48% in both treatment groups at 5 years. Patient satisfaction remained high in both groups (77%), while the percentage of patients indicating that they would have the surgery again was higher in TDR patients (82.5%) than in fusion patients (68.0%). In conclusion, patients in both groups maintained significant improvement during the 5-year follow-up. The TDR group had significantly better improvement on some scales. TDR patients avoid the stiffness of fusion and are more satisfied than fusion patients.

Zigler et al. (59) also reported the 5-year results for radiographically demonstrated ALD changes, using the data from the FDA-mandated postmarket approval study. For the 236 patients in the study, radiographic follow-up data 5 years after treatment were available for 123 TDR patients and 43 fusion patients. To characterize ALD, radiologists at an independent facility read the radiographic films. ALD was characterized by a composite score including disc height loss, endplate sclerosis, osteophytes, and spondylolisthesis. At 5 years, changes in ALD (ΔALDs) compared with the preoperative assessment were reported; ΔALDs were observed in 9.2% of TDR patients and 28.6% of fusion patients (p = 0.004). Among the patients without adjacent-level disease preoperatively, new findings of ALD at 5 years posttreatment were apparent in only 6.7% of TDR patients and 23.8% of fusion patients (p = 0.008). Adjacent-level surgery leading to secondary surgery was reported for 1.9% of TDR patients and 4.0% of fusion patients (p = 0.6819). The TDR patients had a mean preoperative index-level range of motion ([ROM] of 7.3°) that decreased slightly (to 6.0°) at 5 years after treatment (p = 0.0198). Neither treatment group had significant changes in either ROM or translation at the superior adjacent level at 5 years posttreatment compared with baseline. The authors concluded that at 5 years after the index surgery, ProDisc-L maintained ROM and was associated with a significantly lower rate of ΔALDs than in the patients treated with circumferential fusion. In fact, the fusion patients were greater than 3 times more likely to experience ΔALDs than were the TDR patients.

Contract:

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

Coding:

CODING:

Disclaimer for coding information on Medical Policies

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. Only the written coverage position in a medical policy should be used for such determinations.

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT/HCPCS/ICD-9/ICD-10 Codes

The following codes may be applicable to this Medical policy and may not be all inclusive.

CPT Codes

22856, 22857, 22858, 22861, 22862, 22864, 22865, 0095T, 0098T, 0163T, 0164T, 0165T, 0375T

HCPCS Codes

None

ICD-9 Diagnosis Codes

Refer to the ICD-9-CM manual

ICD-9 Procedure Codes

Refer to the ICD-9-CM manual

ICD-10 Diagnosis Codes

Refer to the ICD-10-CM manual

ICD-10 Procedure Codes

Refer to the ICD-10-CM manual


Medicare Coverage:

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <http://www.cms.hhs.gov>.

References:

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2007; Volume 22, Tab 12.

2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2009; Volume 24, Tab 3.

3. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disease of the cervical spine. TEC Assessments. 2011; Volume 26, Tab 5.

4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2013; Volume 28, Tab 13.

5. Mummaneni PV, Burkus JK, Haid RW, et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. J Neurosurg Spine. Mar 2007; 6(3):198-209. PMID 17355018

6. Goffin J, Van Calenbergh F, van Loon J, et al. Intermediate follow-up after treatment of degenerative disc disease with the Bryan Cervical Disc Prosthesis: single-level and bi-level. Spine (Phila Pa 1976). Dec 15 2003; 28(24):2673-2678. PMID 14673368

7. Boselie TF, Willems PC, van Mameren H, et al. Arthroplasty versus fusion in single-level cervical degenerative disc disease: a cochrane review. Spine (Phila Pa 1976). Aug 1 2013; 38(17):E1096-1107. PMID 23656959

8. U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Report of United States Clinical Study Results (G010188) -- Prestige® Cervical Disc System. 2006; Available at < http://www.fda.gov>. Accessed November, 2014.

9. Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. J Manipulative Physiol Ther. Sep 1991; 14(7):409-415. PMID 1834753

10. Burkus JK, Haid RW, Traynelis VC, et al. Long-term clinical and radiographic outcomes of cervical disc replacement with the Prestige disc: results from a prospective randomized controlled clinical trial. J Neurosurg Spine. Sep 2010; 13(3):308-318. PMID 20809722

11. Burkus JK, Traynelis VC, Haid RW, Jr., et al. Clinical and radiographic analysis of an artificial cervical disc: 7- year follow-up from the Prestige prospective randomized controlled clinical trial: Clinical article. J Neurosurg Spine. Oct 2014; 21(4):516-528. PMID 25036218

12. Murrey D, Janssen M, Delamarter R, et al. Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. Spine J. Apr 2009;9(4):275-286. PMID 18774751

13. U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. ProDisc-C Summary of safety and effectiveness data. 2007; <http://www.accessdata.fda.gov>. Accessed November, 2014.

14. Delamarter RB, Murrey D, Janssen ME. Results at 24 months from the prospective, randomized multicenter investigational device exemption trial of ProDisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued access patients. SAS Journal. 2010; 4:122-128.

15. Zigler JE, Delamarter R, Murrey D, et al. ProDisc-C and anterior cervical discectomy and fusion as surgical treatment for single-level cervical symptomatic degenerative disc disease: five-year results of a Food and Drug Administration study. Spine (Phila Pa 1976). Feb 1 2013; 38(3):203-209. PMID 23080427

16. Delamarter RB, Zigler J. Five-year Reoperation Rates, Cervical Total Disc Replacement versus Fusion, Results of a Prospective Randomized Clinical Trial. Spine (Phila Pa 1976). Nov 2 2013; 38(9):711-717. PMID 23124255

17. Nabhan A, Ahlhelm F, Pitzen T, et al. Disc replacement using Pro-Disc C versus fusion: a prospective randomised and controlled radiographic and clinical study. Eur Spine J. Mar 2007; 16(3):423-430. PMID 17106665

18. Heller JG, Sasso RC, Papadopoulos SM, et al. Comparison of BRYAN cervical disc arthroplasty with anterior cervical decompression and fusion: clinical and radiographic results of a randomized, controlled, clinical trial. Spine (Phila Pa 1976). Jan 15 2009; 34(2):101-107. PMID 19112337

19. Sasso RC, Anderson PA, Riew KD, et al. Results of cervical arthroplasty compared with anterior discectomy and fusion: four-year clinical outcomes in a prospective, randomized controlled trial. J Bone Joint Surg Am. Sep 21 2011; 93(18):1684-1692. PMID 21938372

20. Riew KD, Buchowski JM, Sasso R, et al. Cervical disc arthroplasty compared with arthrodesis for the treatment of myelopathy. J Bone Joint Surg Am. Nov 2008; 90(11):2354-2364. PMID 18978404

21. Goffin J, van Loon J, Van Calenbergh F, et al. A clinical analysis of 4- and 6-year follow-up results after cervical disc replacement surgery using the Bryan Cervical Disc Prosthesis. J Neurosurg Spine. Mar 2010; 12(3):261-269. PMID 20192625

22. Cheng L, Nie L, Zhang L, et al. Fusion versus Bryan Cervical Disc in two-level cervical disc disease: a prospective, randomised study. Int Orthop. Oct 2009; 33(5):1347-1351. PMID 18956190

23. Coric D, Nunley PD, Guyer RD, et al. Prospective, randomized, multicenter study of cervical arthroplasty: 269 patients from the Kineflex|C artificial disc investigational device exemption study with a minimum 2-year follow- up: clinical article. J Neurosurg Spine. Oct 2011; 15(4):348-358. PMID 21699471

24. Hadley MN. The real value of cervical arthroplasty? J Neurosurg Spine. Oct 2011;15(4):345-346; discussion 346-347. PMID 21699472

25. U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Summary of Safety and Effectiveness Data: Mobi-C. 2013; Available at <http://www.accessdata.fda.gov>. Accessed November, 2014.

26. Davis RJ, Kim KD, Hisey MS, et al. Cervical total disc replacement with the Mobi-C cervical artificial disc compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial. J Neurosurg Spine. Nov 2013; 19(5):532-545. PMID 24010901

27. Davis RJ, Nunley PD, Kim KD, et al. Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results. J Neurosurg Spine. Nov 7 2014:1-11. PMID 25380538

28. Bae HW, Kim KD, Nunley PD, et al. Comparison of Clinical Outcomes of One and Two-level Total Disc Replacement: 4-year Results from a Prospective, Randomized, Controlled, Multicenter IDE Clinical Trial. Spine (Phila Pa 1976). Mar 17 2015. PMID 25785955

29. Huppert J, Beaurain J, Steib JP, et al. Comparison between single- and multi-level patients: clinical and radiological outcomes 2 years after cervical disc replacement. Eur Spine J. Sep 2011; 20(9):1417-1426. PMID 21336970

30. Phillips FM, Lee JY, Geisler FH, et al. A Prospective, Randomized, Controlled Clinical Investigation Comparing PCM Cervical Disc Arthroplasty With Anterior Cervical Discectomy and Fusion: 2-Year Results From the US FDA IDE Clinical Trial. Spine (Phila Pa 1976). Jul 1 2013; 38(15):E907-918. PMID 23591659

31. U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Summary of Safety and Effectiveness Data: SECURE-C. 2012; Available at <http://www.accessdata.fda.gov>. Accessed November, 2014.

32. Vaccaro A, Beutler W, Peppelman W, et al. Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: two-year results from a prospective, randomized, controlled, multicenter investigational device exemption study. Spine (Phila Pa 1976). Dec 15 2013; 38(26):2227-2239. PMID 24335629

33. Jawahar A, Cavanaugh DA, Kerr EJ, 3rd, et al. Total disc arthroplasty does not affect the incidence of adjacent segment degeneration in cervical spine: results of 93 patients in three prospective randomized clinical trials. Spine J. Dec 2010; 10(12):1043-1048. PMID 20869326

34. Nunley PD, Jawahar A, Kerr EJ, 3rd, et al. Factors affecting the incidence of symptomatic adjacent-level disease in cervical spine after total disc arthroplasty: 2- to 4-year follow-up of 3 prospective randomized trials. Spine (Phila Pa 1976). Mar 15 2012; 37(6):445-451. PMID 21587111

35. Coric D, Cassis J, Carew JD, et al. Prospective study of cervical arthroplasty in 98 patients involved in 1 of 3 separate investigational device exemption studies from a single investigational site with a minimum 2-year follow- up. Clinical article. J Neurosurg Spine. Dec 2010; 13(6):715-721. PMID 21121748

36. Coric D, Kim PK, Clemente JD, et al. Prospective randomized study of cervical arthroplasty and anterior cervical discectomy and fusion with long-term follow-up: results in 74 patients from a single site. J Neurosurg Spine. Jan 2013; 18(1):36-42. PMID 23140129

37. Maldonado CV, Paz RD, Martin CB. Adjacent-level degeneration after cervical disc arthroplasty versus fusion. Eur Spine J. Aug 2011; 20 Suppl 3:403-407. PMID 21796395

38. Fan H, Wu S, Wu Z, et al. Implant failure of Bryan cervical disc due to broken polyurethane sheath: a case report. Spine (Phila Pa 1976). Jun 1 2012; 37(13):E814-816. PMID 22210017

39. Kurtz SM, Toth JM, Siskey R, et al. The Latest Lessons Learned from Retrieval Analyses of Ultra-High Molecular Weight Polyethylene, Metal-on-Metal, and Alternative Bearing Total Disc Replacements. Semin Spine Surg. Mar 1 2012; 24(1):57-70. PMID 22904606

40. Tsermoulas G, Bhattathiri PS. Anterior migration of prosthesis following cervical arthroplasty. Br J Neurosurg. Feb 2013; 27(1):132-133. PMID 22817101

41. Nguyen NQ, Kafle D, Buchowski JM, et al. Ceramic fracture following cervical disc arthroplasty: a case report. J Bone Joint Surg Am. Nov 16 2011; 93(22): e132(131-134). PMID 22262392

42. McAfee PC, Cappuccino A, Cunningham BW, et al. Lower incidence of dysphagia with cervical arthroplasty compared with ACDF in a prospective randomized clinical trial. J Spinal Disord Tech. Feb 2010; 23(1):1-8. PMID 20051917

43. Chen J, Wang X, Bai W, et al. Prevalence of heterotopic ossification after cervical total disc arthroplasty: a meta-analysis. Eur Spine J. Apr 2012; 21(4):674-680. PMID 22134486

44. Yi S, Kim KN, Yang MS, et al. Difference in occurrence of heterotopic ossification according to prosthesis type in the cervical artificial disc replacement. Spine (Phila Pa 1976). Jul 15 2010; 35(16):1556-1561. PMID 20581764

45. Tu TH, Wu JC, Huang WC, et al. Heterotopic ossification after cervical total disc replacement: determination by CT and effects on clinical outcomes. J Neurosurg Spine. Apr 2011; 14(4):457-465. PMID 21294610

46. Cavanaugh DA, Nunley PD, Kerr EJ, 3rd, et al. Delayed hyper-reactivity to metal ions after cervical disc arthroplasty: a case report and literature review. Spine (Phila Pa 1976). Apr 1 2009; 34(7):E262-265. PMID 19333091

47. Guyer RD, Shellock J, MacLennan B, et al. Early failure of metal-on-metal artificial disc prostheses associated with lymphocytic reaction: diagnosis and treatment experience in four cases. Spine (Phila Pa 1976). Apr 1 2011; 36(7):E492-497. PMID 21252827

48. Hacker FM, Babcock RM, Hacker RJ. Very late complications of cervical arthroplasty: results of 2 controlled randomized prospective studies from a single investigator site. Spine (Phila Pa 1976). Dec 15 2013; 38(26):2223- 2226. PMID 24335628

49. Artificial Intervertebral Disc: Cervical Spine. Chicago, Illinois: Blue Cross Blue Shield Association Medical Policy Reference Manual (July 2015) Surgery 7.01.108.

50. Guyer RD, McAfee PC, Banco RJ et al. Prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of lumbar total disc replacement with the CHARITE artificial disc versus lumbar fusion: five-year follow-up. Spine J 2009; 9(5):374-86. PMID 18805066

51. David T. Long-term results of one-level lumbar arthroplasty: minimum 10-year follow-up of the CHARITE artificial disc in 106 patients. Spine. 2007 Mar 15; 32(6):661-6. PMID 17413471

52. Punt IM, Visser VM, et al. Complications and reoperations of the SB Charité lumbar disc prosthesis: experience in 75 patients. Eur Spine J. 2008 Jan; 17(1):36-43. PMID 17929065

53. Resnick DK, Watters WC. Lumbar disc arthroplasty: a critical review. Clin Neurosurg. 2007; 54:83-7. PMID 18504901

54. Huang, R.C., Sandhu, S. (2004). The current status of lumbar total disc replacement. Orthopedic Clinics of North America 35, 33-42.

55. McAfee, P.C., Geisler, F.H., Saiedy, S.S., et al (2006). Revisability of the CharitéTM artificial disc replacement: analysis of 688 patients enrolled in the U.S. IDE study of the CHARITE Artificial Disc. Spine 31, 1217-26.

56. Martin, B.I., Mirza, S.K., Comstock, B.A. et al (2007). Reoperation rates following lumbar spine surgery and the influence of spinal fusion procedures. Spine 32, 382-7. PMID 17268274

57. Malter, A.D., McNeney, B., Loeser, J.D., Deyo, R.A. (1998). 5-year reoperation rates after different types of spinal surgery. Spine 23, 814-20. PMID 9563113

58. Zigler, JE, Delmarter RB. Five-Year Results of Prospective, Randomized, Multicenter, Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement versus circumferential arthrodesis for the treatment of Single-Level Degenerative Disk Disease. J Neurosurg Spine. 2012 Dec: 17(6): 493-501. PMID 23082846

59. Zigler JE, Glenn J, Delamarter RB. Five-year adjacent-level degenerative changes in patients with single-level disease treated using lumbar total disc replacement with ProDisc-L versus circumferential fusion. J Neurosurg Spine. 2012 Dec; 17(6):504-11. Epub 2012 Oct 19.

60. Artificial Intervertebral Disc: Lumbar Spine. Chicago, Illinois: Blue Cross Blue Shield Association Medical Policy Reference Manual (April 2016) Surgery 7.01.87.

61. U. S. Food and Drug Administration. PRODISC-L Summary of safety and effectiveness data. Available at: <http://www.accessdata.fda.gov>. Last accessed February 2016.

62. U. S. Food and Drug Administration. activL® Artificial Disc (P120024). Available at: <http://www.accessdata.fda.gov>. Last accessed February 2017.

Policy History:

Date Reason
11/15/2017 Reviewed. No changes.
4/1/2017 Document updated with literature review. The following phrase: “cleared and used in accordance with the FDA label” was added to the following Lumbar Artificial Intervertebral Disc statement: “Lumbar artificial intervertebral disc, using a disc that is U.S. Food and Drug Administration (FDA) cleared and used in accordance with the FDA label, may be considered medically necessary for patients who meet ALL of the following criteria”.
4/15/2016 Document updated with literature review. Coverage for Cervical Artificial Intervertebral Disc has been divided into Single Level and Two Level criteria. Insertion of a cervical artificial intervertebral disc at two contiguous levels, using a disc approved by the U.S. Food and Drug Administration (FDA), may be considered medically necessary for the treatment of symptomatic degenerative disc disease when criteria are met. Coverage unchanged for Lumbar Artificial Intervertebral Disc.
10/1/2015 Document updated with literature review. Skeletal maturity was added to the listing of medically necessary criteria for coverage of cervical artificial intervertebral disc.
9/15/2014 Document updated with literature review. Coverage unchanged.
4/15/2013 Document updated with literature review. Title changed from “Vertebral Disc Replacement with Artificial Disc”. Lumbar artificial intervertebral disc has changed to the following: Lumbar artificial intervertebral disc, using a disc that has the approval of the U.S. Food and Drug Administration (FDA), may be considered medically necessary for patients who meet ALL of the following criteria: 1) Skeletally mature; AND 2) Degenerative disc disease at only 1 level in the lumbar spine, from L3-S1, confirmed by radiographic studies (CT, MRI, x-rays, etc); AND 3) Have no more than Grade 1 (0-25%) spondylolisthesis at the involved level; AND 4) Minimum Oswestry Disability Index (ODI) score equal to or greater than 40; AND 5) Radicular back/leg pain that has failed a minimum of 6 months of conservative treatment.
2/15/2011 Document updated with literature review. Coverage unchanged.
6/15/2008 Revised/updated entire document. Medical policy title changed. The following has changed: Artificial intervertebral cervical discs may be considered medically necessary when ALL of the following criteria are met: 1) Disc has the approval of the U.S. Food and Drug Administration (FDA); AND 2) Disc will be used for single-level reconstruction (C3-C7) following discectomy; AND 3) Patient has intractable radiculopathy and/or myelopathy due to herniated disc or osteophyte formation; AND 4) Patients has failed at least six weeks of conservative therapy; AND 5) Symptomatic nerve root and/or spinal cord compression documented by ALL the following: a) Neck and/or arm pain; and b) Functional and/or neurological deficit; and c) Radiographic studies (e.g., Computed Tomography (CT), Magnetic Resonance Imaging (MRI), x-rays, etc.).
7/13/2005 New medical document. Artificial intervertebral discs are considered investigational, experimental and/or unproven for replacement of one or more vertebral discs at any level.

Archived Document(s):

Title:Effective Date:End Date:
Artificial Intervertebral Disc03-01-202008-31-2021
Artificial Intervertebral Disc11-15-201702-29-2020
Artificial Intervertebral Disc04-01-201711-14-2017
Artificial Intervertebral Disc04-15-201603-31-2017
Artificial Intervertebral Disc10-01-201504-14-2016
Artificial Intervertebral Disc09-15-201409-30-2015
Artificial Intervertebral Disc04-15-201309-14-2014
Vertebral Disc Replacement with Artificial Disc02-15-201104-14-2013
Vertebral Disc Replacement with Artificial Disc06-15-200802-14-2011
Artificial Vertebral Disc Replacement07-13-200506-14-2008
Back to Top